Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
Journal: The oncologist
Published: February 10, 2025
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Journal: Communications medicine
Published: April 28, 2024
Novel therapies for metastatic prostate cancer.
Journal: Expert review of anticancer therapy
Published: November 29, 2023
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Journal: JCO precision oncology
Published: July 19, 2023
Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 13, 2023
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Journal: Current oncology (Toronto, Ont.)
Published: March 24, 2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Journal: The Prostate
Published: January 25, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026